Peripheral T Cell Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for peripheral t cell lymphoma. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
2
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Peripheral T Cell Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Acrotech Biopharma 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating peripheral t cell lymphoma. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
26
1
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Beleodaq
belinostat
 Acrotech Biopharma 2 73 — 2026-08-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
6888027 Beleodaq method of use 85 2026-08-10
8835501 Beleodaq formulation 60 2027-10-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8835501 Beleodaq formulation 60 2027-10-27
6888027 Beleodaq method of use 85 2026-08-10

Related